<?xml version="1.0" encoding="UTF-8"?>
<p>The study population consisted of a cohort of HIV-infected individuals at an HIV outpatient clinic of a provincial referral hospital in Bandung, Indonesia between 2007 and 2014. Patients are enrolled in this clinic for one of two reasons: (1) a newly diagnosed HIV infection or (2) referral from elsewhere with an indication to start or continue ART. As per 2006 WHO recommendation, indication to start ART at the clinic was baseline CD4 &lt;200 cells/mm
 <sup>3</sup> or WHO clinical stage III or IV–the baseline CD4 limit was increased to &lt;350 cells/mm
 <sup>3</sup> in 2008. Choices of first-line ART offered in the national program are nevirapine (NVP), efavirenz (EFV), zidovudine (ZDV), stavudine (d4T –phased out in 2014), and lamivudine (3TC).
</p>
